Condition: Atrial Fibrillation · Sponsor: National Institute of Cardiology, Warsaw, Poland
SAFE-LAAC Trial has been designed to gather data on the most optimal strategy of antiplatelet therapy after transcatheter left atrial appendage occlusion with Amplatzer or WATCHMAN device
This description comes directly from the study's public registry record.
Radoslaw Pracon, MD PhD · 22 343 43 42 · rpracon@ikard.pl
Marcin Demkow, MD PhD · 22 343 43 42 · mdemkow@ikard.pl
Always discuss trial participation with your own doctor first.
| National Institute of Cardiology | Warsaw, Masovian Voivodeship, Poland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03445949